Oppenheimer Reiterates Outperform Rating on Chemed Corporation (CHE)

Market Context

Chemed Corporation operates in the Healthcare sector. The stock currently trades at $532.25 with a market capitalization of $6.3B. The stock has gained 23.1% over the past 52 weeks.

Analyst coverage from Oppenheimer provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Chemed Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Chemed Corporation

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 31, 2026	Oppenheimer	Outperform	N/A
Jul 30, 2026	RBC Capital	Sector Perform	N/A
Jul 09, 2026	B of A Securities	Neutral	N/A
Apr 27, 2026	RBC Capital	Sector Perform	N/A
Feb 27, 2026	Oppenheimer	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View CHE Stock Page